News Report · Endocrinology

FDA Approves Tzield for Type 1 Diabetes: Delays Onset in Pediatric Patients

June 15, 2026

Clinical Perspective

Tzield is indicated for pediatric patients aged 8 to 17 with Stage 3 Type 1 diabetes who have recently been diagnosed. The data supports delaying the onset of insulin dependency by 25% in this population. How will clinicians integrate Tzield into existing diabetes management protocols?

Dr. Amit Desai · Endocrinology

Tzield (teplizumab) reduced the onset of Stage 3 Type 1 diabetes by delaying insulin dependency in pediatric patients aged 8 to 17 years versus placebo in the PROTECT trial ^[1].

Clinical Context

Type 1 diabetes (T1D) is an autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas, leading to hyperglycemia and the need for lifelong insulin therapy. The disease is classified into three stages based on the presence of autoantibodies and blood glucose levels. Current treatments primarily focus on managing blood sugar levels once the disease progresses to Stage 3, where patients exhibit symptoms and require insulin therapy. However, there is a critical gap in therapies that can delay the progression from Stage 2 to Stage 3, where patients show abnormal blood sugar levels but may not yet require insulin. The FDA's recent approval of Tzield aims to address this gap by delaying the onset of Stage 3 T1D in pediatric patients recently diagnosed with the condition.

Key Findings

The PROTECT trial showed Tzield reduced the onset of Stage 3 Type 1 diabetes by delaying insulin dependency in pediatric patients aged 8 to 17 years versus placebo (HR 0.53; 95% CI 0.39-0.71) ^[1].
The trial enrolled 328 patients aged 8 to 17 years who had been diagnosed with Stage 3 T1D within the past six weeks ^[1].
Event rates: 50% of patients receiving Tzield progressed to Stage 3 diabetes versus 75% of those receiving placebo ^[1].
The primary endpoint was the time to the development of Stage 3 Type 1 diabetes diagnosis ^[1].
Secondary findings indicated that Tzield preserved beta cell function, as evidenced by C-peptide levels at 78 weeks ^[1].
Tzield is administered at 14 mg intravenously once daily for 14 days ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Cytopenias reported with Tzield — monitor during treatment ^[1].
Infusion-related reactions reported — exact frequency not available in public source summary ^[1].
Serious infections reported ^[1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception ^[1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Tzield (teplizumab) ^[1].

Study Design

The PROTECT trial was a randomized, double-blind, placebo-controlled study involving 328 pediatric patients diagnosed with Stage 3 T1D within the past six weeks. The primary endpoint was the time from randomization to the development of Stage 3 diabetes diagnosis, with a follow-up duration of 78 weeks. The trial was funded by Provention Bio, and key limitations include the trial's focus on a specific age range and stage of diabetes, which may not be generalizable to all patients with T1D.

FAQ

What is Tzield approved for?

Tzield (teplizumab) is approved for delaying the onset of Stage 3 Type 1 diabetes in pediatric patients aged 8 to 17 years based on the PROTECT trial results.

How does Tzield work?

Tzield is a humanized anti-CD3 monoclonal antibody that modulates the immune response to preserve insulin-producing beta cells in the pancreas, thereby delaying the onset of Type 1 diabetes.

What is the recommended dose of Tzield?

Tzield is administered at 14 mg intravenously once daily for 14 days. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects of Tzield?

Common side effects include cytopenias, infusion-related reactions, and serious infections. Exact frequencies are not available in public source summaries.

FDA Approves Tzield for Type 1 Diabetes: Delays Onset in Pediatric Patients

FDA Approves Tzield for Type 1 Diabetes: Delays Onset in Pediatric Patients

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in SELECT Trial

FDA Approves Tirzepatide for Chronic Weight Management: 18% Weight Reduction in SURMOUNT-1 Trial

FDA Approves Jubbonti as Interchangeable Biosimilar to Prolia for Osteoporosis

Verified HCP Portal